Section of Vascular Surgery, University of Michigan and Cardiovascular Center, Ann Arbor, Mich., USA.
J Vasc Surg. 2011 Jul;54(1):58-63. doi: 10.1016/j.jvs.2010.11.111. Epub 2011 Feb 2.
Although the natural history and management of infected open abdominal aortic aneurysm (AAA) repair is well described, only sporadic case reports have described the fate of patients with infected endografts placed in the abdominal aorta. The present study describes a tertiary referral center's experience with infected endovascular aneurysm repairs (EVARs).
The medical records of 1302 open and endovascular aortic procedures were queried from January 2000 to January 2010. The cases were reviewed for prior aortic procedures, prosthetic implants, and etiology of current open procedure. Demographics, operative details, and perioperative courses were documented.
Nine patients (1 woman) with a mean age of 71 years had an EVAR that later required an open procedure for explantation and surgical revision for suspected infection. All grafts were explanted through a midline transperitoneal approach, with a mean time to explant of 33 months. The explanted endografts included 4 Zenith (Cook, Bloomington, Ind), 2 Ancure (Endovascular Technologies, Menlo Park, Calif), 2 Excluders (Gore, Flagstaff, Ariz), and 1 AneuRx (Medtronic, Minneapolis, Minn). Eight of the nine original EVARs were performed at other hospitals; 1 patient had EVAR and open explant at the University of Michigan. All patients had preoperative computed tomography scans, except one who was transferred in extremis with a gastrointestinal hemorrhage. Three patients also had a tagged leukocyte scan, and two had magnetic resonance imaging to further reinforce the suspicion of infection before explantation and bypass planning. Rifampin-soaked Hemashield (Boston Scientific) in situ grafts were used in four patients, with extra-anatomic (axillary-bifemoral) bypass used in the other five. The in situ group had no positive preoperative or postoperative cultures, with the exception of the unstable patient who died the day of surgery. For the other five patients, positive tissue cultures were found for Bacteroides, Escherichia coli, coagulase-negative Staphylococcus, Streptococcus, and Candida. Three patients were found to have aortic-enteric fistula, two of whom died before discharge from the hospital. The remaining seven survived to discharge. Average length of stay was 22 days, with a median follow-up of 11 months.
This series of infected EVARs is the largest group of infected AAA endografts reported to date. Because EVAR of AAAs is presently the most common method of repair, development of endograft infection, while rare, can be managed with acceptable mortality rates. Patients presenting with aortic-enteric fistula after EVAR appear to have a more virulent course.
虽然感染性开放性腹主动脉瘤(AAA)修复的自然史和治疗已得到充分描述,但只有零星的病例报告描述了放置在腹主动脉内的感染性血管内移植物的患者的命运。本研究描述了一家三级转诊中心治疗感染性血管内血管修复术(EVAR)的经验。
从 2000 年 1 月至 2010 年 1 月,对 1302 例开放和血管内主动脉手术的病历进行了查询。对先前的主动脉手术、假体植入物和当前开放手术的病因进行了回顾。记录了人口统计学、手术细节和围手术期过程。
9 名(1 名女性)平均年龄 71 岁的患者接受了 EVAR 治疗,随后因疑似感染而需要进行开放手术取出和外科修复。所有移植物均通过中线经腹入路取出,平均取出时间为 33 个月。取出的内移植物包括 4 个 Zenith(库克,印第安纳州布鲁明顿)、2 个 Ancure(Endovascular Technologies,加利福尼亚州门洛帕克)、2 个 Excluders(戈尔,亚利桑那州弗拉格斯塔夫)和 1 个 AneuRx(美敦力,明尼苏达州明尼阿波利斯)。9 例中的 8 例最初的 EVAR 是在其他医院进行的;1 例患者在密歇根大学同时进行了 EVAR 和开放取出。所有患者均进行了术前计算机断层扫描,除 1 例因胃肠道出血而紧急转院的患者外。3 例患者还进行了标记白细胞扫描,2 例患者进行了磁共振成像,以进一步在取出和旁路规划前强化感染的怀疑。在 4 例患者中使用了 Rifampin-soaked Hemashield(波士顿科学公司)原位移植物,另外 5 例患者使用了异位(腋股)旁路。原位组除了当天手术死亡的不稳定患者外,术前和术后均未发现阳性培养物。对于其他 5 例患者,发现了拟杆菌、大肠杆菌、凝固酶阴性葡萄球菌、链球菌和假丝酵母菌的组织培养阳性。3 例患者发现主动脉-肠瘘,其中 2 例在出院前死亡。其余 7 例患者存活至出院。平均住院时间为 22 天,中位随访时间为 11 个月。
本系列感染性 EVAR 是迄今为止报道的最大一组感染性 AAA 内移植物。由于 EVAR 治疗 AAA 目前是最常见的修复方法,虽然感染性内移植物的发生率很低,但可以获得可接受的死亡率。EVAR 后出现主动脉-肠瘘的患者似乎具有更具侵袭性的病程。